Mucosta (Rebamipide)


Indications and Reactions:

Role Indications Reactions
Secondary
Pyrexia 14.7%
Malignant Glioma 14.0%
Drug Use For Unknown Indication 10.5%
Bronchitis 9.8%
Ill-defined Disorder 8.4%
Otitis Media Acute 7.7%
Product Used For Unknown Indication 5.6%
Hypertension 3.5%
Analgesic Therapy 2.8%
Chronic Sinusitis 2.8%
Gastrooesophagitis 2.8%
Streptococcal Infection 2.8%
Back Pain 2.1%
Glaucoma 2.1%
Pain In Extremity 2.1%
Prophylaxis 2.1%
Rheumatoid Arthritis 2.1%
Cerebrovascular Accident Prophylaxis 1.4%
Depression 1.4%
Drug Eruption 1.4%
Stomatitis 14.3%
Respiratory Arrest 10.7%
Vomiting 10.7%
Interstitial Lung Disease 7.1%
Anosmia 3.6%
Cardiac Failure 3.6%
Chronic Hepatitis 3.6%
Enteritis 3.6%
Erythromelalgia 3.6%
Liver Disorder 3.6%
Lymphocyte Stimulation Test Positive 3.6%
Malaise 3.6%
Multiple Drug Overdose Intentional 3.6%
Nasal Polyps 3.6%
No Adverse Event 3.6%
Pain In Extremity 3.6%
Pyelonephritis 3.6%
Rhabdomyolysis 3.6%
Skin Ulcer 3.6%
Spinal Osteoarthritis 3.6%
Concomitant
Multiple Myeloma 22.9%
Rheumatoid Arthritis 12.8%
Lung Adenocarcinoma 10.9%
Drug Use For Unknown Indication 8.3%
Lupus Nephritis 4.8%
Acute Myeloid Leukaemia Recurrent 4.1%
Diabetes Mellitus 3.7%
Lung Squamous Cell Carcinoma Stage Unspecified 3.7%
Hypertension 3.1%
Osteoporosis 3.0%
Acute Myeloid Leukaemia 2.9%
Lung Transplant 2.9%
Cerebral Infarction 2.7%
Non-small Cell Lung Cancer 2.6%
Prophylaxis 2.6%
Non-hodgkin's Lymphoma 2.2%
Diabetes Mellitus Non-insulin-dependent 1.8%
Hyperphosphataemia 1.8%
Epilepsy 1.6%
Sinusitis 1.6%
White Blood Cell Count Decreased 24.8%
Rash 8.4%
Platelet Count Decreased 7.0%
Vomiting 6.6%
Interstitial Lung Disease 5.6%
Pyrexia 5.2%
Respiratory Failure 4.9%
Stomatitis 4.2%
Tumour Lysis Syndrome 3.8%
Upper Respiratory Tract Inflammation 3.8%
Sepsis 3.1%
Viral Infection 3.1%
Rhabdomyolysis 2.8%
White Blood Cell Count Increased 2.8%
Malignant Neoplasm Progression 2.4%
Pneumonia 2.4%
Renal Impairment 2.4%
Renal Failure Acute 2.1%
Skin Ulcer 2.1%
Thrombocytopenia 2.1%

Drug Data